NEXS BioMedica

06/20/2025

Early detection just took a giant leap forward: a Johns Hopkins study shows that multicancer early detection (MCED) tests can spot tumor-derived DNA in the bloodstream up to 3.5 years before clinical diagnosis—flagging eight out of 52 participants (all within four months of their cancer diagnosis) and retroactively detecting mutations in four cases more than three years prior . This breakthrough gives physicians a critical head start, catching tumors when they’re smallest and most treatable.

At NEXS BioMedica, we’re excited about the synergy this creates with our ribotoxic stress + SAPK modulation therapy and AI/ML “Ribosomal Collision Intensity Score” platform. By combining ultra-early molecular detection with our precision dosing regimens for Adrenocortical Carcinoma, triple-negative breast cancer, glioblastoma, and more, we can intervene sooner—maximizing curative potential, reducing side effects, and fundamentally shifting the oncology paradigm. Together, early detection and targeted therapy will bring real hope to patients facing even the hardest-to-treat cancers.

06/20/2025

Big news in early cancer detection: GRAIL’s Galleri® PATHFINDER 2 study just reported a 43% positive predictive value, 99.5% specificity, and 88% cancer signal‐origin accuracy across 25,578 asymptomatic adults—significantly outperforming their initial PATHFINDER results .

This breakthrough means we’re closer than ever to a single blood test that can flag dozens of cancers before symptoms arise. For NEXS BioMedica, integrating Galleri’s multi-cancer detection with our ribotoxic-stress + SAPK therapy platform could transform patient pathways—screening high-risk individuals, refining our AI/ML “Ribosomal Collision Intensity Score,” and accelerating enrollment into our Adrenocortical Carcinoma, TNBC, and glioblastoma trials.

By partnering diagnostics with targeted treatment, we can catch cancers earlier, personalize dosing schedules in real time, and drive superior outcomes
https://grail.com/press-releases/grail-announces-positive-top-line-results-from-the-galleri%e2%93%a1-pathfinder-2-registrational-study/

06/03/2025

The FDA is using AI to cut red tape and accelerate new-drug reviews. For small biotechs like NEXS BIOMEDICA working on rare cancers, this could be a real game-changer—here’s why.

Artificial intelligence (AI) is reshaping industries worldwide, and drug development is no exception. The U.

04/02/2025

Check out the new NEXS BioMedica- Horizons Commercial

02/26/2025

Thrilled to announce that our sister company, NEXS Technology, has been accepted into the AWS Startup Program. This achievement accelerates the development of CancerScope-AI—our advanced AI tool transforming cancer research and precision medicine. With AWS powering our efforts, we're one step closer to improving outcomes for cancer patients. Congratulations to the NEXS Technology Group team; we are proud to be on this journey together.

02/22/2025

NEXS BioMedica is proud to launch CancerScope-AI, a revolutionary AI tool with NEXS Technology Group. It’s bringing hope to rare cancer patients—smart tech for a tough fight. Check it out: https://www.nexsbiomedica.com

NEXS BioMedica Unveils CancerScope-AI: A Game-Changer in Rare Cancer Treatment. NEXS BioMedica, a forward-thinking biotech pharmaceutical company, proudly introduces CancerScope-AI, an innovative artificial intelligence system set to transform the battle against rare cancers. - PR13063247

02/22/2025

‘A Lifeline Preserved or a Mirage of Relief?’ It’s about a federal judge pausing NIH funding cuts that could’ve gutted research—including NEXS BioMedica’s work on Adrenocortical carcinoma, a rare killer. The Trump admin’s push could reshape biotech—will it spark innovation or choke it? Read the stakes for us and countless others fighting to save lives. Link in bio/comments!

February 21, 2025 — Today, a federal judge’s gavel struck a temporary blow against the Trump administration’s aggressive push to slash NIH…

02/21/2025

Big win for science today: a federal judge extended the block on NIH funding cuts, halting a 15% cap on indirect costs. For NEXS BioMedica, this means critical research stays funded—labs keep running, ideas keep growing. For the broader biomedical community, it’s a lifeline: no slashed budgets, no stalled trials, just a chance to keep pushing the boundaries of innovation. Resilience is paying off, but the fight’s not over—stay vigilant. Here’s to science thriving against the odds.

02/21/2025

February 21, 2025—In biopharma, the ground’s shaking: NIH funding’s on the chopping block (Washington Post), but the pulse of innovation beats stronger than ever—think AI breakthroughs and rare disease wins (GOV.UK, CBS). At NEXS BIOMEDICA, we’re not flinching. As CEO, I’m leading our charge against adrenocortical carcinoma—a rare killer with too little hope—blending biopharmaceutical grit with next-gen tech. Yesterday’s patent filing marks our latest strike, and we’re chasing an NIH SBIR to fuel it.

This isn’t just science—it’s a fight for patients stuck with outdated options. We’re crafting a future where ACC meets its match. Who’s with us to redefine healthcare’s tough corners? Drop your thoughts below. hashtag hashtag hashtag hashtag hashtag hashtag

02/20/2025

February 20, 2025—biotech’s facing headwinds, but at NEXS BIOMEDICA, we’re charging forward. With NIH budgets under fire (Washington Post) and AI breakthroughs lighting the way (GOV.UK), the moment to innovate is now. As Chairman, I’m steering us toward rare cancer solutions—advancing a drug candidate and harnessing AI to crack complex data. We filed a provisional patent today to lock in our latest leap, prepping for an NIH SBIR push by April 5. In a world of cuts and chaos (Reuters), we’re betting on precision and grit to transform rare cancer care. How do we keep this fight alive? Let’s talk.

02/18/2025

At NEXS BioMedica, we’re a leading biotech pharmaceutical company dedicated to advancing healthcare. With innovative research and development in areas like oncology, immunology, and beyond, our cutting-edge solutions are transforming patient care and redefining what’s possible in medicine.

Discover how our passion for precision science is creating breakthrough therapies and shaping the future of healthcare. Visit us at https://www.nexsbiomedica.com to learn more about our journey and innovations.

“We aren’t just imagining the future; we’re creating it.”

02/16/2025

From Blockbuster Ambitions to a Life-Saving Mission: How a Call from My Friend with ACC Changed My Course

My journey began with a singular focus—to create a blockbuster drug, a groundbreaking GLP-1 agonist that would revolutionize metabolic disease treatment. I was deeply immersed in developing an innovative delivery system that promised to set new standards in precision medicine.